HLA class I expression on human cancer cells: Implications for effective immunotherapy

Human Immunology

Volumn 61, Issue 2, 2000, Pages 158-165

  Tait, Brian D ^a  

^a ROYAL MELBOURNE HOSPITAL   (Australia)

Author keywords

Cancer vaccines; Expression; HLA class I; Immunoselection; Tumours

Indexed keywords

CANCER VACCINE; HLA ANTIGEN CLASS 1;

ALLELE; ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; CANCER CELL; CANCER IMMUNOTHERAPY; CONFERENCE PAPER; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; GENE LOCUS; HUMAN; HUMAN CELL; IMMUNITY; PRIORITY JOURNAL;

ANIMALS; ANTIGEN PRESENTATION; ANTIGENS, NEOPLASM; CANCER VACCINES; HISTOCOMPATIBILITY ANTIGENS CLASS I; HLA ANTIGENS; HUMANS; IMMUNOTHERAPY; NEOPLASMS; T-LYMPHOCYTES; VACCINES, DNA;

EID: 0033969037     PISSN: 01988859     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0198-8859(99)00150-0     Document Type: Conference Paper

References (89)

1. Zinkernagel R.M., Doherty P.C. Restriction of in vitro T cell-mediated cytotoxicity in lymphocytic choriomeningitis within a syngeneic or semiallogeneic system. Nature. 248:1974;701.
2. Bjorkman P.J., Saper M.A., Samraoui B., Bennett W.S., Strominger J.L., Wiley D.C. Structure of the human class I histocompatibility antigen HLA-A2. Nature. 329:1987;506.
3. Brown J.H., Jardetzky T.S., Gorga J.C., Stern L.J., Urban R.G., Strominger J.L., Wiley D.C. Three-dimensional structure of the human class II histocompatibility antigen HLA-DR1. Nature. 364:1993;33.
4. Gross L. Intradermal immunization of C3H mice against a sacroma that originated in an animal of the same line. Cancer Res. 3:1943;326.
5. Foley E.J. Antigenic properties of methylcholanthrene induced tumours in mice of the strain of origin. Cancer Res. 13:1953;835.
6. Prehn R.T., Main J.M. Immunity to methycholanthrene induced sarcomas. J Natl Cancer Inst. 18:1957;769.
7. Klein G., Sjogren H.O., Klein E., Hellstrom K.E. Demonstration of resistance against methylcholanthrene induced sarcomas in the primary autochthonous host. Cancer Res. 20:1960;1561.
8. Habel K. Immunological determinants of polyoma virus oncogenesis. J Exp Med. 115:1962;181.
9. Klein G., Clifford P., Klein E., Stjernsward J. Search for tumour specific immune reactions in Burkitt lymphoma patients by the membrane immunofluorescence reaction. PNAS. 55:1966;1628.
10. Klein G., Klein E., Clifford P. Search for host differences in Burkitts lymphoma membrane immunofluorescence tests on biopsies and tissue culture lines . Cancer Res. 27:1967;2510.
11. Klein G., Clifford P., Klein E., Smith R.T., Minowada J., Kourilsky F.M., Burchenal J.H. Membrane immunofluorescence reactions of Burkitt lymphoma cells from biopsy specimens and tissue cultures. J Natl Cancer Inst. 39:1967;1027.
12. Southam C.M., Brunschwig A., Levin A.G., Dizon Q.S. Effect of leukocytes on transplantability of human cancer. Cancer. 19:1966;1743.
13. Hellstrom I.E., Hellstrom K.E., Pierce G.E., Bill A.H. Demonstration of cell bound and humoral immunity against neuroblastoma cells. PNAS. 60:1968;1231.
14. Hellstrom I.E., Hellstrom K.E., Pierce G.E., Yang J.P.S. Cellular and humoral immunity to different types of human neoplasms. Nature. 220:1968;1352.
15. Rosenberg S.A., Packard B.S., Aebersold P.M., Solomon D., Topalian S.L., Toy S.T., Simon P., Lotze M.T., Yang J.C., Seipp C.A., Simpson C., Carter C., Boch S., Schwartzentruber D., Wei J.P., White D.E. Use of tumour infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma A preliminary report . N Engl J Med. 319:1988;1676.
16. Baars J.W., Fonk J.C., Scheper R.J., von Blomberg-van der Flier B.M., Bril H., von Valk P., Pinedo H.M., Wagstaff J. Treatment with tumor infiltrating lymphocytes and interleukin-2 in patients with metastatic melanoma a pilot study . Biotherapy. 4:1992;289.
17. Itoh K., Tilden A.B., Baich C.M. Interleukin-2 activation of cytotoxic T lymphocytes infiltrating into human metastic carcinomas. Cancer Res. 46:1986;3011.
18. Kradin R.L., Kurnick J.T., Lazarus D.S., Preffer F.I., Dubinett S.M., Pinto C.E., Gifford J., Davidson E., Grove B., Callhan R.J., Strauss H.W. Tumour infiltrating lymphocytes and interleukin-2 in treatment of advanced cancer. Lancet. 18:1989;577.
19. Aoki Y., Takakuwa K., Kodama S., Tanaka K., Takahashi M., Tokunaga A., Takahashi T. Use of adoptive transfer of tumour infiltrating lymphocytes alone or in combination with cisplatin containing chemotherapy in patients with epithelial ovarian cancer. Cancer Res. 51:1991;1934.
20. Germain R.N., Castellino F., Han R., Reis E., Sousa C., Romagnoli P., Sadegh-Nasseri S., Zhong G.-M. Processing and presentation of endocytically acquired protein antigens by MHC class II and class I molecules. Immunol Rev. 151:1996;5.
21. Van Der Bruggen P., Traversari C., Chomez P., Lurquin C., De Plaen E., Van Den Eynde B., Knuth A., Boon T. A gene encoding an antigen recognised by cytolytic T lymphocytes on a human melanoma. Science. 254:1991;1643.
22. Traversari C., Van Der Bruggen P., Luescher I.F., Lurquin C., Chomez P., Van Pel A., De Plaen E., Amar-Costesec A., Boon T. A nonapeptide encoded by human gene MAGE-1 is recognised on HLA-A1 by cytolytic T lymphocytes directed against tumour antigen MZ2-E. J Exp Med. 176:1992;1453.
23. Van Der Bruggen P., Szikora J.P., Boel P., Wildmann C., Somville M., Sensi M., Boon T. Autologous cytolytic T lymphocytes recognise a MAGE-1 nonapeptide on melanomas expressing Cw1601. Eur J Immunol. 24:1994;2134.
24. Gaugler B., Van Den Eynde B., Van Der Bruggen P., Romero P., Gaforio J.J., De Plaen E., Lethe B., Brasseur F., Boon T. Human gene MAGE-3 codes for an antigen recognised on a melanoma by autologous cytolytic T lymphocytes. J Exp Med. 179:1994;921.
25. Boel P., Wildmann C., Sensi M.L., Brasseur R., Renauld J.-C., Coulie P., Boon T., Van Der Bruggen P. BAGE a new gene encoding an antigen recognised on human melanomas by cytolytic T lymphocytes . Immunity. 2:1995;167.
26. Van Den Eynde B., Peeters O., De Backer O., Gaugler B., Lucas S., Boon T. A new family of genes coding for an antigen recognised by autologous cytolytic T lymphocytes on a human melanoma. J Exp Med. 182:1995;689.
27. Van Der Bruggen P., Bastin J., Gajewski T., Coulie P.G., Boel P., De Smet C., Traversari C., Townsend A., Boon T. A peptide encoded by human gene MAGE-3 and presented by HLA-A2 induces cytolytic T lymphocytes that recognise tumour cells expressing MAGE-3. Eur J Immunol. 24:1994;3038.
28. Wolfel T., Van Pel A., Brichard V., Schneider J., Seliger B., Buschenfelde K.-H., Boon T. Two tyrosinase nonapeptides recognised on HLA-A2 melanomas by autologous cytolytic T lymphocytes. Eur J Immunol. 24:1994;759.
29. Kawakami Y., Eliyahu S., Sakaguchi K., Robbins P.F., Rivoltini L., Yannelli J.R., Appella E., Rosenberg S.A. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognised by the majority of HLA-A2 restricted tumour infiltrating lymphocytes. J Exp Med. 180:1994;347.
30. Kawakami Y., Eliyahu S., Delgado C.H., Robbins P.F., Sakaguchi K., Appella E., Yannelli J.R., Adema G.J., Miki T., Rosenberg S.A. Identification of a human melanoma antigen recognised by tumour-infiltrating lymphocytes associated with in vivo tumour rejection. PNAS. 91:1994;6458.
31. Coulie P.G., Lehmann F., Lethe B., Herman J., Lurquin C., Andrawiss M., Boon T. A mutated intron sequence codes for an antigenic peptide recognised by cytolytic T lymphocytes on a human melanoma. PNAS. 92:1995;7976.
32. Wolfel T., Hauer M., Schneider J., Serrano M., Wolfel C., Klehmann-Hieb E., De Plaen E., Hankeln T., Buschenfelde K.-H., Beach D. A p16 INK4a insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science. 269:1995;1281.
33. Robbins P.F., El-Gamil M., Li Y.F., Kawakami Y., Loftus D., Appella E., Rosenberg S.A. A mutated β-catenin gene encodes a melanoma specific antigen recognised by tumour infiltrating lymphocytes. J Exp Med. 183:1996;1185.
34. Apostopoulos V., McKenzie I.F.C. Cellular mucins targets for immunotherapy . Crit Rev Immunol. 14:1994;293.
35. Diederichsen A.C., Stenholm A.C., Kronborg O., Fenger C., Jensenius J.C., Zeuthen J. Immunisation of colorectal cancer patients with autologous tumour cells. Oncol Rep. 5:1998;823.
36. Stingl G., Brocker E.B., Mertelsmann R., Wolff K., Schreiber S., Kampgen E., Schneeberger A., Drummer W., Brennscheidt U., Veelken H., Birnstiel M.L., Zatloukal K., Schmidt W., Maass G., Wagner E., Baschle M., Giese M., Kempe E.R., Weber H.A., Voigt T. Phase 1 study to the immunotherapy of metastatic malignant melanoma by a cancer vaccine consisting of autologous cancer cells transfected with the human IL-2 gene. Hum Gene Ther. 7:1996;551.
37. Stingl G., Brocker E.B., Mertelsmann R., Wolff K., Schreiber S., Kampgen E., Schneeberger A., Trcka J., Brennscheidt U., Veelken H., Birnstiel M.L., Zatloukal K., Maass G., Wagner E., Buschle M., Kempe E.R., Weber H.A., Voigt T. Phase 1 study to the immunotherapy of metastatic malignant melanoma by a cancer vaccine consisting of autologous cancer cells transfected with the human IL-2 gene. J Mol Med. 75:1997;297.
38. Parmiani G., Arienti F., Sule-Suso J., Melani C., Colombo M.P., Ramakrishna V., Belli F., Mascheroni L., Rivoltini L., Cascinelli N. Cytokine based gene therapy of human tumours An overview . Folia Biol. 42:1996;305.
39. Cascinelli N., Foa R., Parmiani G., Arienti F., Belli F., Bernengo M.G., Clemente C., Colombo M.P., Guarini A., Illeni M.T. Active immunisation of metastatic melanoma patients with interleukin-4 transduced allogeneic melanoma cells A phase I-II study . Hum Gene Ther. 5:1994;1059.
40. Moller P., Sun Y., Dorbic T., Alijagic S., Makki A., Jurgovsky K., Schroff M., Henz B.M., Wittig B., Schadendorf D. Vaccination with IL-7 gene-modified autologous melanoma cells can enhance the anti-melanoma lytic activity in peripheral blood of patients with a good clinical performance status a clinical phase I study . Br J Cancer. 77:1998;1907.
41. Seigler H.F., Darrow T.L., Abdel-Wahab Z., Gangavalli R., Barber J. A phase 1 trial of human gamma inteferon transduced autologous tumour cells in patients with disseminated malignant melanoma. Hum Gene Ther. 5:(6):1994;761.
42. Henze G., Borgmann A., Von Stackelberg A., Baumgarten E., Uchanska-Ziegler B., Ziegler A., Wittig B. Immunotherapy of acute lymphoblastic leukaemia by vaccination with autologous leukaemic cells transfected with a cDNA expression plasmid coding for an allogeneic HLA class I antigen combined with interleukin-2 treatment. J Mol Med. 76:1998;215.
43. Hoon D.S.B., Yuzuki D., Hayashida M., Morton D.L. Melanoma patients immunised with melanoma cell vaccine induce antibody responses to recombinant MAGE-1 antigen. J Immunol. 154:1995;730.
44. Hoon D.S.B., Okamoto T., Wang H.J., Elashoff R., Nizze A.J., Foshag L.J., Gammon G., Morton D.L. Is the survival of melanoma patients receiving polyvalent melanoma cell vaccine linked to the human leukocyte antigen phenotype of patients? J Clin Oncol. 16:1998;1430.
45. Das Gupta T.K., Cohen E.P., Richards J.M. Phase I evaluation of interleukin-2 transfected irradiated allogeneic melanoma cells for the treatment of metastatic melanoma appendix 1: protocol . Hum Gene Ther. 8:1997;1701.
46. Gilboa E., Nair S.K., Lyerly H.K. Immunotherapy of cancer with dendritic-cell-based vaccines. Cancer Immunol Immunother. 46:1998;82.
47. Buschle M., Schmidt W., Zauner W., Mechtler K., Trska B., Kirlappos H., Birnstiel M.L. Transloading of tumour antigen derived peptides into antigen presenting cells. Proc Natl Acad Sci. 94:1997;3256.
48. De Bruijn M.L.H., Schuurhuis D.H., Vierboom M.P.M., Vermeulen H., De Cock K.A.J., Ooms M.E., Ressing M.E., Toebes M., Franken K.L.M.C., Drijfhout J.-W., Ottenhoff T.H.M., Offringa R., Melief C.J.M. Immunisation with human papillomavirus type 16 (HPV 16) oncoprotein-loaded dendritic cells as well as protein in adjuvant induces MHC class I-restricted protection to HPV 16-induced tumour cells. Cancer Res. 58:1998;724.
49. Karanikas V., Hwang L.A., Pearson J., Ong C.S., Apostolopoulos V., Vaughan H., Xing P.X., Jamieson G., Pietersz G., Tait B.D., Broadbent R., Thynne G., Mckenzie I.F.C. Antibody and T cell responses of patients with adenocarcinoma immunised with mannan-Muc 1 fusion protein. J Clin Invest. 100:1997;2783.
50. Apostolopoulos V., Mckenzie I.F.C., Pietersz G.A. Breast cancer immunotherapy current status and future prospects . Immunol Cell Biol. 74:1996;457.
51. Bystryn J.C. Clinical activity of a polyvalent melanoma antigen vaccine. Recent Results Cancer Res. 139:1995;337.
52. Bystryn J.C., Jacobsen S., Harris M., Roses D., Spever J., Levin M. Preparation and characterization of a polyvalent human melanoma antigen vaccine. J Biol Response Mod. 5:1986;211.
53. Wallack M.K., Bash J., Bartolucci A. Improvement in disease-free survival of melanoma patients in conjuction with serologic response in a phase 1a/1b Southeastern Cancer Study Group trial of vaccinia melanoma oncolysate . Am J Surg. 55:1989;243.
54. Wallack M.K., Sivanandham M., Ditaranto K., Shaw P., Balch C.M., Urist M.M., Bland K.I., Murray D., Robinson W.A., Flaherty L., Richards J.M., Rosen L., Bartolucci A.A. Increased survival of patients treated with a vaccinia melanoma oncolysate vaccine second interim analysis of data from a phase III multi institutional trial . Ann Surg. 226:1997;198.
55. Wallack M.K., Sivanandham M., Balch C.M., Urist M.M., Bland K.I., Murray D., Robinson W.A., Flaherty L., Richards J.M., Bartolucci A.A., Rosen L. Surgical adjuvant active specific immunotherapy for patients with stage III melanoma the final analysis of data from a phase III, randomised double-blind multicenter vaccinia melanoma oncolysate trial . J Am Coll Surg. 187:1998;69.
56. Foon K.A., Sen G., Hutchins L., Kashala O.L., Baral R., Banerjee M., Chakraborty M., Garrison J., Reisfeld R.A., Bhattacharva-Chatterjee M. Antibody responses in melanoma patients immunised with an anti-idiotype antibody mimicking disialoganglioside GD2. Clin Cancer Res. 4:1998;1117.
57. Chatterjee S.K., Tripathi P.K., Chakraborty M., Yannelli J., Wang H., Foon K.A., Maier C.C., Blalock J.E., Bhattacharva-Chatterjee M. Molecular mimicry of carcinoembryonic antigen by peptides derived from the structure of an anti-idiotype antibody. Cancer Res. 58:1998;1217.
58. Nabel G.J., Yang Z.Y., Nabel E.G., Bishop K., Marquet M., Felgner P.L., Gordon D., Chang A.E. Direct gene transfer for treatment of human cancer. Ann NY Acad Sci. 772:1995;227.
59. Nabel G.J., Nabel E.G., Yang Z.-Y., Fox B.A., Plautz G.E., Gao X., Huang L., Shu S., Gordon D., Change A.E. Direct gene transfer with DNA-liposome complexes in melanoma expression, biologic activity and lack of toxicity in humans . PNAS. 90:1993;11307.
60. Restifo N.P. The new vaccines builidng viruses that elicit antitumour immunity . Curr Opin Immunol. 8:1996;658.
61. Tuting T., Storkus W.J., Falo L.D. DNA immunisation targeting the skin Molecular control of adaptive immunity . J Invest Dermatol. 111:1998;183.
62. Pan Z.K., Ikonomidis G., Pardoll D., Paterson Y. Regression of established tumours in mice mediated by the oral administration of a recombinant Listeria monocytogenes vaccine. Cancer Res. 55:1995;4776.
63. Paterson Y., Ikonomidis G. Recombinant listeria monocytogenes cancer vaccines. Curr Opin Immunol. 8:1996;664.
64. D'Angelica M., Fong Y. Cytokine gene therapy for human tumours. Surg Oncol Clin NA. 7:1998;537.
65. Tuting T., Storkus W.J., Lotze M.T. Gene-based strategies for the immunotherapy of cancer. J Mol Med. 75:1997;478.
66. Redondo M., Concha A., Oldiviela R., Cueto A., Gonzales A., Garrido F., Ruiz-Cabello F. Expression of HLA class I and II antigens in bronchogenic carcinomas its relationship to cellular DNA content and clinical-pathological parameters . Cancer Res. 51:1991;4948.
67. Cabrera T., Fernandez A.M., Sierra A., Garrido A., Herruzo A., Escobedo A., Fabra A., Garrdio F. High frequency of altered HLA class I phenotypes in invasive breast carcinomas. Hum Immunol. 50:1996;127.
68. Concha A, Cabrera T, Ruiz-Cabello F, Garrido F: Can the HLA phenotype be used as a prognostic factor in breast carcinomas? Int J Cancer (Suppl. 6):146, 1991.
69. Blades R.A., Keating P.J., McWilliam L.J., George N.J.R., Stern P.L. Loss of HLA class I expression in prostate cancer implications for immunotherapy . Urology. 46:1995;681.
70. Concha A., Esteban F., Cabrera T., Ruiz-Cabello F., Garrido F. Tumour aggressiveness and MHC class I and II antigens in laryngeal and breast cancer. Sem Cancer Biol. 2:1991;47.
71. Esteban F., Redondo M., Delgado M., Garrido F., Ruiz-Cabello F. MHC class I antigens and tumour infiltrating leukocytes in laryngeal cancer long term follow-up . Br J Cancer. 74:(2):1996;1801.
72. Natali P.G., Nicotra M.R., Bigotti A., Venturo I., Marcenaro L., Giacomini P., Russo C. Selective changes in expression of HLA class I polymorphic determinants in human solid tumours. PNAS. 86:1989;6719.
73. Hilders C.G., Munoz I.M., Nooyen Y., Fleuren G.J. Altered HLA expression by metastatic cervical carcinoma cells as a factor in impaired immune surveillance. Gynecol Oncol. 57:1995;366.
74. Torres M.J., Ruiz-Cabello F., Skoudy A., Berrozpe G., Jimenez P., Serrano A., Real F.X., Garrido F. Loss of an HLA haplotype in pancreas cancer tissue and its corresponding tumour derived cell line. Tissue Antigens. 47:1996;372.
75. Kaklamanis L., Leek R., Koukourakis M., Gatter K.C., Harris A.L. Loss of transporter in antigen processing/transport protein and major histocompatibility complex class I molecules in metastatic versus primary breast cancer. Cancer Res. 55:1995;5191.
76. Hirata S., Yamazaki K., Kubo Y., Matsui H. DNA content analysis and expression of human leukocyte antigen on oesophageal cancer. Rinsho Byori. 43:1995;227.
77. Redondo M., Concha A., Ruiz-Cabello F., Morell M., Esteban F., Talavera P., Garrido F. Class I major histocompatibility complex antigens and tumour ploidy in breast and bronchogenic carcinomas. Cancer Detect Prev. 21:1997;22.
78. Klein B., Levin I., Klein T. HLA class I antigen expression in human solid tumours. Isr J Med Sci. 32:1996;1238.
79. Zheng P., Guo Y., Niu Q., Levy D.E., Dyck J.A., Lu S., Sheiman L.A., Liu Y. Proto-oncogene PML control genes devoted to MHC class I presentation. Nature. 396:1998;373.
80. Garrido F., Cabrera T., Lopez-Nevot M.A., Ruiz-Cabello F. HLA class I antigens in human tumours. Adv Cancer Res. 67:1995;155.
81. Blom D.J., Luyten G.P., Mooy C., Kerkvliet S., Zwinderman A.H., Jager M.J. Human leukocyte antigen class I expression Marker of poor prognosis in uveal melanoma . Invest Opthalmol Vis Sci. 38:1997;1865.
82. Komatsu F., Kajiwara M. Comparison of natural killer (NK) senstivities of two tumour cell lines established from a cancer patient before and after radiation therapy. Clin Immunol Immunopathol. 82:1997;190.
83. Paul P., Rouas-Freiss N., Khalil-Daher I., Moreau P., Riteau B., Le Gal F.A., Avril M.F., Dausset J., Guillet J.G., Carosella E.D. HLA-G expression in melanoma a way for tumour cells to escape from immunosurveillance . PNAS. 95:1998;4510.
84. Ishigami S., Aikou T., Natsugoe S., Hokita S., Iwashige H., Tokushige M., Sonoda S. Prognostic value of HLA-DR expression and dendritic cell infiltration in gastric cancer. Oncology. 55:1998;65.
85. Scupoli M.T., Sartoris S., Tosi G., Ennas M.G., Nicolis M., Cestari T., Zamboni G., Martignoni G., Lemoine N.R., Scarpa A., Accolla R.S. Expression of MHC class I and class II antigens in pancreatic adenocarcinomas. Tissue Antigens. 48:1996;301.
86. Gastl G., Ebert T., Finstad C.L., Sheinfeld J., Gomahr A., Aulitzky W., Bander N.H. Major histocompatibility complex class I and class II expression in renal cell carcinoma and modulation by interferon gamma. J Urol. 155:1996;361.
87. Lazaris A.C., Theodoropoulos G.E., Davaris P.S., Panoussopoulos D., Nakopoulou L., Kittas C., Golematis B.C. Heat shock protein 70 and HLA-DR molecules tissue expression Prognostic implications in colorectal cancer . Dis Colon Rectum. 38:1995;739.
88. Morita M., Tanaka K., Kawanishi H., Tsuji M., Ookusa T., Takada H., Okamura A., Hioki K. Immunohistochemically demonstrated expression of HLA-DR antigen in colorectal adnocarcinomas and its relation to clinicopathological features. J Surg Oncol. 59:1995;233.
89. Diederichsen A.C., Hansen T.P., Nielsen O., Fenger C., Jensenius J.C., Christiansen P.B., Kristensen T., Zeuthen J. A comparison of flow cytometry and immunohistochemistry in human colorectal cancers. APMIS. 106:1998;562.